Congress Themes

New Insights into the pathogenesis of facioscapulohumeral muscular dystrophy, myotonic dystrophy and other dominant muscular dystrophies

Update in laminopathies : phenotypes, pathogenesis and therapie, Nicolas Levy, France
Myotonic dystrophy: can mechanistic insight translate into therapeutic success? Charles Thornton, USA
A contribution of " junk DNA " and transcription factors to the molecular mechanism of FSHD, Alexandra Belayew, Belgium
Facioscapulohumeral muscular dystrophy: transition from a mendelian trait to a complex genetic disease?, Rossella Tupler, USA
Genetic and epigenetic studies of FSHD, S Van der Maarel, Netherlands

Congenital myasthenic syndromes and the formation of the neuromuscular junction, David Beeson, UK
Auto antibody mediated effector Mechanisms in Myasthenia Gravis and its animal model: about antibodies and anchor proteins, Marc De Baets, Netherlands
The congenital myasthenias. An overview, Andy Engel, USA
Autoimmune Myasthenia: Clinical Aspects, Amelia Evoli, Italy
Congenital myasthenic syndromes - diagnosis and therapy, Hanns Lochmuller, UK
What We Can Learn from Animal Models of Myasthenia Gravis, Diane Shelton, USA

Re-establishment of dystrophin expression by exon skipping and/or trans-splicing approaches, Luis Garcia, France
The rationale for immunosuppressive treatment in DMD and first results of the German CsA/PRED-trial, Rudolf Korinthenberg, Germany
Preclinical Drug Trial Efforts for Muscular Dystrophy: Methods and End points, Kanneboyina Nagaraju, USA
Translational Research in Neuromuscular Diseases - where do we stand?, Volker Straub, UK
Splice manipulation therapies: opportunities and challenges, Steve Wilton, Australia